1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML
    Meeting Abstract

    Stone, R. M.; Choe, S.; Zhang, V.; Marteyn, B.; Penard-Lacronique, V.; Wang, H.; DiNardo, C. D.; Stein, E. M.; Fathi, A. T.; Tallman, M. S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations
    Meeting Abstract

    Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S. M.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo Coco, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Real world clinical and economic burden of patients with Hodgkin lymphoma (HL) who fail frontline (FL) therapy in the US
    Meeting Abstract

    Straus, D. J.; Bonafede, M.; Feliciano, J.; Cai, Q.; Noxon, V.; Princic, N.; Josephson, N.; Richhariya, A.
    Blood (2017)

    Fulltext@MSK | Save
  • Characterization of NTRK fusions and therapeutic response to NTRK inhibition in hematologic malignancies
    Meeting Abstract

    Taylor, J.; Marcelus, C.; Pavlick, D.; Benayed, R.; Yoshimi, A.; Cocco, E.; Durham, B. H.; Hechtman, J. F.; Chung, Y. R.; Mullaney, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Romiplostim for chemotherapy-induced thrombocytopenia (CIT). Results of a phase 2 trial
    Meeting Abstract

    Soff, G. A.; Miao, Y.; Devlin, S. M.; Mantha, S.; Mones, J. V.; Li, V. J.; Abou-Alfa, G. K.; Cercek, A.; Kemeny, N.; Parameswaran, R.
    Blood (2017)

    Fulltext@MSK | Save
  • Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time
    Meeting Abstract

    Stein, E. M.; Stone, R. M.; Pollyea, D. A.; Roboz, G. J.; Altman, J. K.; DiNardo, C. D.; de Botton, S.; Tu, N.; Swern, A. S.; Tosolini, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A validated risk model for overall survival in relapsed/refractory chronic lymphocytic leukemia applicable to patients treated with novel therapies and standard of care
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Huang, J.; Lin, M.; Byrd, J. C.; Chanan-Khan, A. A.; Furman, R. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in the United States
    Meeting Abstract

    Stein, E. M.; Xie, J.; Duchesneau, E.; Bhattacharyya, S.; Ndife, B.; Bonifacio, G.; Joseph, G. J.
    Blood (2017)

    Fulltext@MSK | Save
  • Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone-marrow transplantation in mice
    Meeting Abstract

    Staffas, A.; da Silva, M. B.; Slingerland, A. E.; Lazrak, A.; Shono, Y.; Durham, B. H.; Stein-Thoeringer, C. K.; Docampo, M.; Jay, H. V.; Lieberman, S. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative (ALCL, ALK-): Analysis of 203 patients prospectively registered in the International T-Cell Project
    Meeting Abstract

    Shustov, A.; Cabrera, M. E.; Bellei, M.; Ko, Y. H.; Manni, M.; Horwitz, S. M.; De Souza, C. A.; Radford, J. A.; Varela, S. B.; Prates, M. V.; more...
    Blood (2017)

    Fulltext@MSK | Save